Literature DB >> 8846397

Comparative distribution of receptors for amylin and the related peptides calcitonin gene related peptide and calcitonin in rat and monkey brain.

G Christopoulos1, G Paxinos, X F Huang, K Beaumont, A W Toga, P M Sexton.   

Abstract

The distribution of amylin receptors (125I-labelled rat amylin) in brains of rat and monkey were mapped and compared with the distribution of receptors for calcitonin (CT) (125I-labelled salmon CT) and calcitonin gene related peptide (CGRP) (rat, 125I-labelled rat CGRP alpha; monkey, 125I-labelled human CGRP alpha. In rat, amylin receptors were discretely distributed with the highest receptor densities found in mid-caudal accumbens nucleus, parts of the bed nucleus of the stria terminalis, amygdala, and hypothalamus. Moderate to high densities of binding also occurred in the area postrema, subfornical organ, vascular organ of the lamina terminalis, locus ceruleus, dorsal raphe, and caudal solitary tract nucleus. In monkey, the distribution of amylin binding sites was similar, although the highest densities of receptors were in the hypothalamus, with relatively fewer sites present in the accumbens nucleus. In rat, the distribution of amylin receptors formed a subset of the receptor distributions for 125I-labelled salmon CT and 125I-labelled rat CGRP alpha. In contrast, in monkey, although the amylin receptors again formed a subset of the binding sites identified with 125I-labelled salmon CT, there was very little overlap with the pattern of CGRP receptor distribution. This suggests that the specificity profile of amylin receptors in primates differs from that of amylin receptors in the rat, with CGRP alpha having relatively lower affinity for the primate amylin receptors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8846397     DOI: 10.1139/y95-146

Source DB:  PubMed          Journal:  Can J Physiol Pharmacol        ISSN: 0008-4212            Impact factor:   2.273


  19 in total

1.  CGRP receptors mediating CGRP-, adrenomedullin- and amylin-induced relaxation in porcine coronary arteries. Characterization with 'Compound 1' (WO98/11128), a non-peptide antagonist.

Authors:  P Hasbak; A Sams; S Schifter; J Longmore; L Edvinsson
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

2.  Enhanced nicotine self-administration and suppressed dopaminergic systems in a rat model of diabetes.

Authors:  Laura E O'Dell; Luis A Natividad; Joseph A Pipkin; Francisco Roman; Ivan Torres; Jesus Jurado; Oscar V Torres; Theodore C Friedman; John M Tenayuca; Arbi Nazarian
Journal:  Addict Biol       Date:  2013-07-08       Impact factor: 4.280

3.  Amylin receptor signaling in the nucleus accumbens negatively modulates μ-opioid-driven feeding.

Authors:  Sarah K Baisley; Brian A Baldo
Journal:  Neuropsychopharmacology       Date:  2014-06-24       Impact factor: 7.853

Review 4.  Pancreatic signals controlling food intake; insulin, glucagon and amylin.

Authors:  Stephen C Woods; Thomas A Lutz; Nori Geary; Wolfgang Langhans
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

Review 5.  Amylin activates distributed CNS nuclei to control energy balance.

Authors:  Elizabeth G Mietlicki-Baase; Matthew R Hayes
Journal:  Physiol Behav       Date:  2014-01-28

6.  Phasic and sustained fear are pharmacologically dissociable in rats.

Authors:  Leigh Miles; Michael Davis; David Walker
Journal:  Neuropsychopharmacology       Date:  2011-04-06       Impact factor: 7.853

7.  Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974).

Authors:  Simon R Sinclair; Stefanie A Kane; Bart J Van der Schueren; Alan Xiao; Kenneth J Willson; Janet Boyle; Inge de Lepeleire; Yang Xu; Lisa Hickey; William S Denney; Chi-Chung Li; John Palcza; Floris H M Vanmolkot; Marleen Depré; Anne Van Hecken; M Gail Murphy; Tony W Ho; Jay N de Hoon
Journal:  Br J Clin Pharmacol       Date:  2010-01       Impact factor: 4.335

8.  Amylin receptor signaling in the ventral tegmental area is physiologically relevant for the control of food intake.

Authors:  Elizabeth G Mietlicki-Baase; Laura E Rupprecht; Diana R Olivos; Derek J Zimmer; Mark D Alter; R Christopher Pierce; Heath D Schmidt; Matthew R Hayes
Journal:  Neuropsychopharmacology       Date:  2013-03-08       Impact factor: 7.853

9.  Amylin modulates the mesolimbic dopamine system to control energy balance.

Authors:  Elizabeth G Mietlicki-Baase; David J Reiner; Jackson J Cone; Diana R Olivos; Lauren E McGrath; Derek J Zimmer; Mitchell F Roitman; Matthew R Hayes
Journal:  Neuropsychopharmacology       Date:  2014-07-18       Impact factor: 7.853

Review 10.  Pramlintide for the treatment of insulin-requiring diabetes mellitus: rationale and review of clinical data.

Authors:  Davida F Kruger; Maurice A Gloster
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.